The study demonstrated the safety and resistance of Osimertinib and Savolitinib in patients with advanced NSCLC (n = 18) who had previously advanced disease after EGFR-TKI treatment [61,62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.